Akebia Therapeutics
AKBA
171 hedge funds and large institutions have $141M invested in Akebia Therapeutics in 2026 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 41 increasing their positions, 53 reducing their positions, and 28 closing their positions.
68% more call options, than puts
Call options by funds: $933K | Put options by funds: $557K
32% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 28
4% more funds holding
Funds holding: 165 → 171 (+6)
6.57% less ownership
Funds ownership: 44.54% → 37.96% (-6.6%)
23% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 53
26% less capital invested
Capital invested by funds: $190M → $141M (-$48.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$1.66M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.57M |
| 3 |
Jane Street
New York
|
+$1.05M |
| 4 |
Millennium Management
New York
|
+$1M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$786K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.85M |
| 3 |
Renaissance Technologies
New York
|
-$2.42M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.08M |
| 5 |
Goldman Sachs
New York
|
-$1.52M |
AKBA Hedge Fund Activity: Q1 2026 in Review
171 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2026, worth a combined $141M — down 26% from $190M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new AKBA positions and 28 closed out — a net gain of 9 holders — while 41 added to existing stakes and 53 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $1.66M. The largest seller was Citadel Advisors, cutting an estimated $4.5M.
- 171 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2026, up from 165 in Q4 2025.
- Funds reported $141M of Akebia Therapeutics stock for Q1 2026, down 26% quarter-over-quarter.
- 37 funds opened new Akebia Therapeutics positions in Q1 2026 and 28 closed out, a net change of +9 holders.
- The largest Akebia Therapeutics buyer in Q1 2026 was Two Sigma Investments, an estimated $1.66M added.
- The largest Akebia Therapeutics seller in Q1 2026 was Citadel Advisors, an estimated $4.5M sold.
Based on aggregated 13F filings for Q1 2026.